An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants

Chan, Kui K., Tan, Timothy J. C., Narayanan, Krishna K., Procko, Erik·2021·Science Advances
DOI 10.1126/sciadv.abf1738

Cited by (152)

Items 101–152 of 152

  1. Deep mutational scanning and CRISPR-engineered viruses: tools for evolutionary and functional genomics studies
    Mercedes Paz, Gonzalo Moratorio · 2025 · mSphere
  2. Soluble wild-type ACE2 molecules inhibit newer SARS-CoV-2 variants and are a potential antiviral strategy to mitigate disease severity in COVID-19
    Rohan Ameratunga, Emily Mears, Euphemia Yee Leung, Russell G. Snell, See‐Tarn Woon, William Kelton, Natalie J. Medlicott, Anthony Jordan, William G.H. Abbott, Richard Henderson Steele et al. · 2023 · Clinical & Experimental Immunology
  3. Coronavirus Entry Inhibitors
    Qiaoshuai Lan, Shuai Xia, Lu Lu · 2022 · Advances in experimental medicine and biology
  4. in silico Assessment of Antibody Drug Resistance to Bamlanivimab of SARS-CoV-2 Variant B.1.617
    Leili Zhang, Tien Huynh, Binquan Luan · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  5. ACE2, From the Kidney to SARS-CoV-2: Donald Seldin Award Lecture 2023
    DANIEL C. BATLLE, Luise Hassler, Jan A Wysocki · 2024 · Hypertension
  6. The role of chemical biology in the fight against SARS-CoV-2
    George M. Burslem · 2021 · Biochemical Journal
  7. Features of Highly Homologous T-Cell Receptor Repertoire in the Immune Response to Mutations in Immunogenic Epitopes
    Ksenia V. Zornikova, Dmitry Vladimirovich Dianov, N. O. Ivanova, Vassa D Davydova, Tatiana A. Nenasheva, Ekaterina I. Fefelova, Боголюбова Аполлинария Васильевна · 2024 · International Journal of Molecular Sciences
  8. Structural impact of synonymous mutations in six SARS-CoV-2 Variants of Concern
    A. Ziesel, H. Jabbari · 2024 · bioRxiv
  9. Polypharmacology in Drug Design and Discovery—Basis for Rational Design of Multitarget Drugs
    Zhiguo Wang, Baofeng Yang · 2022 · Springer eBooks
  10. Variation Analysis of SARS-CoV-2 Complete Sequences from Iran
    Jale Moradi, Parnia Moradi, Amirhooshang Alvandi, Ramin Abiri, Mohsen Moghoofei · 2022 · Future Virology
  11. Susceptibility and Resistance of SARS-CoV-2 Variants to LCB1 and Its Multivalent Derivatives
    Hongliang Jin, Yani Gong, Lin Cheng, Yuanmei Zhu, Zheng Zhang, Yuxian He · 2023 · Viruses
  12. ACE2-Targeting Monoclonal Antibody as Potent and Broad-Spectrum Coronavirus Blocker
    Yuning Chen, Yanan Zhang, Renhong Yan, Guifeng Wang, Yuanyuan Zhang, Zherui Zhang, Yaning Li, Jianxia Ou, Wendi Chu, Zhijuan Liang et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  13. Investigation of the Mutations in the SARS-CoV-2 Envelope Protein and Its Interaction with the PALS1 by Molecular Docking
    Maryam Ajel, Seyed Mohammad Jazayeri, Emad Behboudi, Mansour Poorebrahim, Mahin Ahangar Oskouee, Hossein Bannazadeh Baghi, Alka Hasani, Mojtaba Varshochi, Ali Akbar Shekarchi, Mohammad Sabbaghian et al. · 2024 · Reports of Biochemistry and Molecular Biology
  14. Rational design of a covalent ACE2 decoy receptor that broadly neutralizes SARS ‐ CoV ‐2 variants
    Nobumasa Hino, Risa Takada, Kyosuke Suzuki, Nagisa Tokunoh, Tatsuya Karaki, Kazumasa Ohtake, Haruna Ogami, Takafumi Nishiura, Kenji Ishimoto, Tomohito Tsukamoto et al. · 2025 · Protein Science
  15. Evolutionary Insight into Fatal Human Coronaviruses (hCoVs) with a Focus on Circulating SARS-CoV-2 Variants Under Monitoring (VUMs)
    Mohammad Asrar Izhari, Fahad Alghamdi, Essa Ajmi Alodeani, A Salem, Ahamad H. A. Almontasheri, Daifallah M. M. Dardari, Mansour A. A. Hadadi, Ahmed R. A. Gosady, Wael A. Alghamdi, Bakheet A. Alzahrani et al. · 2025 · Biomedicines
  16. Engineered Receptor Capture Combined with Mass Spectrometry Enables High-Throughput Detection and Quantitation of SARS-CoV-2 Spike Protein
    Neil Bate, Dan Lane, Siân E. Evans, Farah Salim, Natalie Allcock, Richard Haigh, Julian E. Sale, Donald J. L. Jones, Nicholas P.J. Brindle · 2025 · JACS Au
  17. Unlocking capacities of viral genomics for the COVID-19 pandemic response
    Sergey Knyazev, Karishma Chhugani, Varuni Sarwal, Ram Ayyala, Singh, Harman, Smruthi Karthikeyan, Dhrithi Deshpande, Zoia Comarova, Angela Lu, Yuri B. Porozov et al. · 2021 · PubMed
  18. A CNN model for predicting binding affinity changes between SARS-CoV-2 spike RBD variants and ACE2 homologues
    Chen Chen, Veda Sheersh Boorla, Ratul Chowdhury, Ruth Helmus Nissly, Abhinay Gontu, Shubhada K. Chothe, Lindsey Cecelia LaBella, Padmaja Jakka, Santhamani Ramasamy, Kurt J. Vandegrift et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  19. Deep mutational scanning of whole SARS-CoV-2 spike in an inverted infection system
    Shunta Taminishi, Songling Li, Yusuke Higuchi, Yuhei Kirita, Daisuke Motooka, Yuki Ozaki, Takao Arimori, Nariko Ikemura, Yumi Itoh, Satoaki Matoba et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  20. Utilizing noncatalytic ACE2 protein mutant as a competitive inhibitor to treat SARS-CoV-2 infection
    Shengjiang Liu, Haifeng Chen, Xiangqun Chen, Ningguang Luo, Sameera Peraramelli, Xiaoming Gong, Mingwei John Zhang, Li Ou · 2024 · Frontiers in Immunology
  21. Molecular insights into Dalbavancin's blockade of ACE2-spike protein interaction in SARS-CoV-2
    Zhongbo Liu, Yuxi Lv, Song Luo, Lili Duan · 2024 · Physical Chemistry Chemical Physics
  22. The Relation of Angiotensin-Converting Enzyme 2, Renin-Angiotensin-Aldosterone System Inhibitors, and Arterial Stiffness in Acute COVID-19 Emergency Department Patients—A Prospective Observational Study
    Sebastian Schnaubelt, Anna Jakobljevich, Roman Brock, Julia Oppenauer, Andrea Kornfehl, Felix Eibensteiner, Christoph Veigl, Thomas Perkmann, Helmuth Haslacher, Robert Paul Straßl et al. · 2025 · Journal of Clinical Medicine
  23. Angiotensin Converting Enzyme 2 is a molecular decoy for targeted photodynamic SARS-CoV-2 inactivation
    Andrea Mussini, Matteo Mariangeli, Pietro Delcanale, Stefania Abbruzzetti, Paolo Bianchini, Alberto Diaspro, Davide Lelli, Ana Maria Moreno, Cristiano Viappiani · 2025 · International Journal of Biological Macromolecules
  24. An engineered chimeric ACE2-HR2 peptide exhibits potent and broad-spectrum activity against SARS-CoV-2 variants
    Wenwen Bi, Tao Zhu, Yawen Xu, Yihui Chen, Jianmin Li · 2025 · Antiviral Research
  25. Multivalent decoy receptor therapeutics to combat viral pandemics and evolution
    Alex Odoom, Eugene Marfo Obeng, Christian K. O. Dzuvor · 2025 · Trends in Pharmacological Sciences
  26. Susceptibility of broad reactivity nanobodies to resistance mutations in the S2 domain of SARS-CoV-2 predicted by yeast display deep mutational scanning
    Christina Ball, Walter Ramage, Ryan Mate, Simon E. Hufton · 2026 · Frontiers in Immunology
  27. Human angiotensin‑converting enzyme 2‑specific benzothiazole-based allosteric inhibitor against pan‑sarbecoviruses
    Li Liu, Jinxin Bai, Runhong Zhou, Yao Ma, Dongyan Zhou, Terrence Tsz‐Tai Yuen, Wenwu Liu, Pok-Man Lai, Wenjun Yu, Jianxin Duan et al. · 2026 · Nature Communications
  28. Immunology of SARS-CoV-2 Infection
    Aida G. Gabdoulkhakova, Rimma N. Mingaleeva, Albina M. Romozanova, Aisylu R. Sagdeeva, Филина Юлия Викторовна, Albert Anatolyevich Rizvanov, Мифтахова Регина Рифкатовна · 2024 · Biochemistry (Moscow)
  29. Comprehensive Evaluation of ACE2-Fc Combination with Neutralization Antibody on Broad Protection against SARS-CoV-2 and Its Variants
    Hao-Neng Tang, Y. Ke, Han-Hui Ma, Lei Han, Lei Wang, Huifang Zong, Yunsheng Yuan, Zhen-Yu Wang, Yang He, Yunsong Chang et al. · 2022 · bioRxiv
  30. Novel ACE2 nanoparticles universally block SARS-CoV-2 variants in the human respiratory tract
    Cécile Sauvanet, Moara Lemos, Armel Bezault, Borja Rodríguez de Francisco, Michael C. W. Chan, Kenrie P. Y. Hui, Ka‐Chun Ng, John Malcolm Nicholls, Niels Volkmann, Dorit Hanein · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  31. Computational Prediction of Binding Affinities of Human Angiotensin Converting Enzyme-2 with SARS-CoV-2 Spike Protein Variants: Omicron Variants and Potentially Deleterious Mutations
    Alexander H. Williams, Chang‐Guo Zhan · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  32. Evaluation of Mutation in Spike Gene of Covid-19 in Iranian Patients
    Mohammad Gholami, Negin Hosseini Rouzbahani, Hamed Naghoosi, Sajad Fani-Kheshti, Seyyed‐Javad Hosseini‐Shokouh · 2022 · Annals of Military and Health Sciences Research
  33. Recombinant Human ACE2-Fc : A promising therapy for SARS-CoV2 infection
    Smitha P.K., R.K. Shandil, Pushkarni Suresh, Kunal Biswas, Gudepalya Renukaiah Rudramurthy, Chakenahalli N. Naveenkumar, K. Bharathkumar, Naga Puspha Battula, Suprabuddha Datta Chowdhury, Sakshi Sinha et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  34. Deep mutational scanning to predict antibody escape in SARS-CoV-2 Omicron subvariants
    Mellissa C. Alcantara, Yusuke Higuchi, Yuhei Kirita, Satoaki Matoba, Atsushi Hoshino · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  35. Superiority of intranasal over systemic administration of bioengineered soluble ACE2 for survival and brain protection against SARS-CoV-2 infection
    Luise Hassler, Jan A Wysocki, Jared T. Ahrendsen, Minghao Ye, Ian Arthur Gelarden, Vlad I. Nicolaescu, Αναστασία Τοματσίδου, Haley Gula, Cosimo L. Cianfarini, Nigar Anjuman Khurram et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  36. ACE2Fc: A Promising Therapy for SARS-Cov2 Infection
    P. K. Smitha, R.K. Shandil, Pushkarni Suresh, Kunal Biswas, Gudepalya Renukaiah Rudramurthy, Chakenahalli N. Naveenkumar, K. Bharathkumar, Naga Puspha Battula, Suprabuddha Datta Chowdhury, Sakshi Sinha et al. · 2022 · Medical Research Archives
  37. SARS-CoV-2: Structure, Pathogenesis, and Diagnosis
    Aarthi Goverdhan · 2023 · Elsevier eBooks
  38. The role of the renin-angiotensin-aldosterone system in the development of cardiovascular complications in COVID-19
    Михаил Маркович Забежинский, Anastasia A. Semenova · 2023 · Pediatrician (St Petersburg)
  39. Current Progress in Genomic and Genetic Research on Human Viral Diseases
    2024 · Frontiers research topics
  40. Immunology of SARS-CoV-2 infection
    Aida G. Gabdoulkhakova, Rimma N. Mingaleeva, Albina M. Romozanova, Aisylu R. Sagdeeva, Филина Юлия Викторовна, Albert Anatolyevich Rizvanov, Мифтахова Регина Рифкатовна · 2024 · Biochemistry (Moscow)
  41. A combinatorial and computational Tandem approach towards a universal therapeutics against ACE2-mediated coronavirus infections
    Chia Yin Lee, Ching-Wen Huang, Louis De Falco, Rabiatul Adawiyah Minhat, Aurélien Traversier, Bei Wang, Siti Nazihah Mohd Salleh, Eve Zi Xian Ngoh, Yuling Huang, Jenna Kim et al. · 2025 · iScience
  42. Coronavirus variants, viral mutation and COVID-19 vaccines: The science you need to understand
    Richard Kuhn · 2021
  43. Receptor-mediated mechanisms underlying neurological complications in COVID-19: from viral entry to neuroinflammation
    Digbijoy Nath, Abdullah Al Noman, Sanjana Pradhan, Pranav Sharma, Sahidur Ahmed, Firuza Begum, Md Al Hafiz, Emad M. Abdallah · 2026 · 3 Biotech
  44. Engineering nasally delivered IgM antibodies for respiratory viral infections
    Ashwin Kumar Ramesh, Zhiqiang An · 2026 · hLife
  45. Scanning the horizon: deep mutational scanning approaches in virology
    Jack Dorman, William Bakhache, Patrick Dolan · 2026 · Journal of Virology
  46. Production of mannosylated hrsACE2 by baculovirus expression system; the way to remove and redirect SARS-CoV-2 viral particles to macrophages
    Bahareh Vakili, Bahareh Vakili, Nafiseh Esmaeil, Marc Gordon Aucoin, Ali Jahanian‐Najafabadi · 2026 · Biotechnology Letters
  47. Size‐Dependent Neutralization Efficacy of Nanodecoys Against SARS‐CoV‐2 Mimics in Mammalian Cell Infection Models
    Nan Li, Xuejian Li, Yuchen Guo, Daiwei Zhang, Xiangfu Du, Zihao Teng, Aijie Liu, Lizhi Zhou, Zhihuan Liao, Shuaidong Huo · 2026 · Small
  48. ACE2-PNA conjugates exploit viral endocytosis for targeted intracellular delivery and exhibit dual antiviral efficacy against SARS-CoV-2
    Yifei Wang, Jinghan Xu, Yiquan Chen, Xin Xiao, Yiru Zhu, Liyang Yu, Wen Shi, Jingchao Li, Jianhua Li, Chenggang Zhu · 2026 · Molecular Biomedicine
  49. Viral receptors as host–pathogen control nodes linking entry, signalling, and system-level pathogenesis
    Salvatore Furnari, Guido Attilio Condorelli, Giorgio Gallinella, Virginia Fuochi, Pio Maria Furneri · 2026 · FEMS Microbiology Reviews
  50. Dual-targeting engineered binding proteins block SARS-CoV-2 infection and complement activation
    Fan Pu, Yiwan Guo, Xinni Pan, Xin Liu, Fan Yang · 2026 · Antiviral Research
  51. Epigenetic regulation of DPP4 receptor expression by NONO enables replication of MERS-CoV
    Adam Hage, Mikhaila Janes, Seth D. Scott, Suhyeon Yoon, Kevin Rose, Tovah E. Markowitz, Lara M. Myers, Aaron Carmody, Lenny Triem, Olivia Straw et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  52. Small-molecule drug conjugates as a novel strategy against emerging respiratory viruses, such as influenza viruses and SARS-CoV-2
    Paweł Zmora · 2026 · Annual reports in medicinal chemistry